Both the U.S. government and its European Union counterparts are spending billions of dollars to encourage new product development aimed at combating flu and bioterrorism. In this session, U.S. and EU industry experts from public and private sectors will detail exactly what incentives, programs and business models are available to encourage new product development, focusing on U.S. and EU government strategies regarding influenza preparedness and biodefense, including legislative actions, intended outcomes, procurement requirements, expected challenges and opportunities.



Objectives:

Examine U.S. and European public health security and biodefense needs.

Inform the participants of what incentives, programs and business models are available and have been set up to encourage new product development.

Provide new insight into the strengths, weaknesses, opportunities and threats associated with the global vaccine and biodefense marketplace.